Medical oncologist, currently working as an attending physician in the Medical Oncology Department at the Catalan Institute of Oncology in Girona, which is integrated into the Dr. Josep Trueta University Hospital. Specialized in gynecologic oncology and sarcomas. I am also an associate professor in the Department of Medical Sciences, where I teach Gynecology and Bioethics, as well as in the Master's Program in Comprehensive Oncology at the same university.
My professional and academic journey began with a residency in Medical Oncology in Girona in 2015, completing the five-year training program in May 2020, which included a two-month external rotation at the Montefiore Cancer Center (NYC), under the mentorship of Dr. Gucalp.
As a researcher, I participate in phase I–IV clinical trials and registry-based observational studies. I am an active member of the Spanish Ovarian Cancer Research Group (GEICO) and the Spanish Sarcoma Research Group (GEIS), forming part of the gynecologic sarcomas subgroup. Additionally, I belong to the European Society for Medical Oncology (ESMO) and obtained certification through the annual ESMO Examination for Medical Oncologists in 2019.
I earned my PhD from the University of Girona in March 2023 and obtained a Master’s Degree in Molecular Oncology from Rey Juan Carlos University in 2019. My research career began during the COVID-19 pandemic, with the publication of four research articles in high-impact international journals as part of the European OnCovid Study Group. These studies explored the interaction between cancer and COVID-19, demonstrating that age and comorbidity burden were the primary determinants of infection outcomes, beyond oncologic characteristics.
I began my doctoral thesis on melanoma during my final year of residency (2019–2020), focusing on the population epidemiology of cutaneous and mucosal melanoma, as well as the molecular analysis of commonly mutated genes in melanoma. As part of this work, 30 mucosal melanomas diagnosed in Girona between 1994 and 2018 were sequenced, with results published in the journal Cancers. I also contributed to documenting rare immunotherapy-related toxicities through real-world data and the publication of a clinical case.
I continue to publish relevant case reports that provide evidence for managing complex clinical scenarios not addressed in current guidelines.
My most recent scientific article focuses on new lines of research in endometrial cancer (DOI: 10.20960/revcancer.00094).
Currently, I collaborate with multiple researchers across Spain on various projects, such as DAYDREAM, which retrospectively evaluates the effectiveness of adjuvant chemotherapy in high-grade uterine sarcomas, and DORA, which assesses the effect of dostarlimab in endometrial cancer using real-world data. Results from the DAYDREAM project and the DORA study (P-049) were presented in an oral communication at the ESGO Congress in Barcelona 2024.
Additionally, Dr. Carbó participates in national observational registries on gynecologic cancers and sarcomas coordinated by GEICO and GEIS, respectively (GEIS-78 and GEICO 81-T). Internationally, she is involved in the Immune4All project, which analyzes both retrospectively and prospectively the HRD test data in ovarian cancer patients treated with first-line platinum-based chemotherapy followed by maintenance therapy.